Patents Examined by Tara Martinez
-
Patent number: 9884000Abstract: Described herein are tooth whitening strips comprising an hydratable adhesive film having a granular bleaching ingredient attached thereto, wherein upon hydration, the granular bleaching ingredient releases hydrogen peroxide which is used by an enzyme catalyst having perhydrolytic activity to enzymatically produce an effective amount of peracid bleaching agent from an acyl donor substrate. Methods of making and use the tooth whitening strips are also provided.Type: GrantFiled: December 18, 2012Date of Patent: February 6, 2018Assignees: Colgate-Palmolive Company, E.I. Du Pont De Nemours and CompanyInventors: Thomas J. Boyd, Guofeng Xu, Richard Adams, Robert Pierce, Steven Miller, David Viscio, Kari A. Fosser, Robert Dicosimo, Hong Wang
-
Patent number: 9884124Abstract: The invention provides carriers that enhance the absorption, half-life or bioavailability of therapeutic compounds. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties.Type: GrantFiled: February 6, 2016Date of Patent: February 6, 2018Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Howard P. Sard, Mukkanti Amere
-
Patent number: 9822148Abstract: Provided are a substance capable of binding to EGFR specifically with a high affinity and a pharmaceutical agent containing the substance. A peptide which contains at least an amino acid sequence is represented by the formula (1), (2) or (3), as described in the specification, and is composed of 12 to 50 amino acids: (SEQ?ID?NO:?55) X1-His-X2-X3-Asp-X4-X5-X6-X7-X8-Trp-His(1) (SEQ?ID?NO:?56) Phe-His-Asp-Trp-X11-Pro-X12-X13-X14-X15-X16-X17(2) (SEQ?ID?NO:?57) Leu-His-X21-Ser-X22-Trp-Met-X23-X24-X25-X26-X27(3).Type: GrantFiled: June 18, 2013Date of Patent: November 21, 2017Assignee: HOYA CORPORATIONInventors: Yusuke Iimori, Mizue Yamagata, Toshitaka Shiono
-
Patent number: 9822155Abstract: A method of preventively treating a subject at the risk of developing infections of a respiratory virus is disclosed. The method includes a step of administering to the subject an effective amount of a peptide synthesized through a chemical route or by a genetic engineering process, characterized in that the peptide has a functional domain capable of binding to a surface glycoprotein of a respiratory virus and has an activity of inhibiting infection of the respiratory virus, wherein the peptide has 5 or more basic amino acids, among which 2 or more basic amino acids are in N-terminal region or C-terminal region of the peptide; and wherein the peptide consists of an amino acid sequence that is at least 90% identical to SEQ ID NO: 10. The invention also discloses the mechanism of the peptides in inhibition of said infections, which provides theory support for developing new prophylactic/therapeutic agents with broad-spectrum antiviral activities.Type: GrantFiled: August 23, 2016Date of Patent: November 21, 2017Assignee: Xiangxue Group (Hong Kong) Company LimitedInventors: Bojian Zheng, Hanjun Zhao
-
Patent number: 9823254Abstract: Provided herein, inter alia, are methods and compositions for removing a phosphopantethiene analog moiety from an ACP-phosphopantetheine conjugate thereby providing Apo-ACP proteins.Type: GrantFiled: March 13, 2015Date of Patent: November 21, 2017Assignee: The Regents of the University of CaliforniaInventors: Michael D. Burkart, Nicolas M. Kosa, Robert W. Haushalter
-
Patent number: 9801921Abstract: The present application relates to the use of a pertussis toxin, and its derivatives, analogs, salts and pharmaceutical equivalents. In one embodiment, the invention provides a method of treating an autoimmune disease by administering pertussis toxin to the individual. In another embodiment, the autoimmune disease is multiple sclerosis. In another embodiment, the invention provides a method of treating a neurodegenerative disease such as Alzheimer's disease or Parkinson's disease by administering pertussis toxin, or a derivative, analog, salt or pharmaceutical equivalent.Type: GrantFiled: June 29, 2012Date of Patent: October 31, 2017Assignee: DIGNITY HEALTHInventor: Jiong Shi
-
Aqueous solution comprising a macromolecular conjugate of heparin for the treatment of blood vessels
Patent number: 9795629Abstract: The present invention relates to a solution for treating blood vessels where the solution comprises a heparin conjugate. The invention further relates to the use of the conjugate as a medicament and a method of coating tissue using the conjugate.Type: GrantFiled: December 17, 2012Date of Patent: October 24, 2017Assignee: CORLINE SYSTEMS ABInventor: Rolf Larsson -
Patent number: 9775879Abstract: The present invention relates to a use of a human small leucine zipper protein in the adipocyte differentiation procedure. More specifically, sLZIP binds with PPAR?2 to induce the formation of a complex of HDAC3 and PPAR?2, thereby functioning as a corepressor to negatively inhibit the transcriptional activity of PPAR?2 and suppress the differentiation to adipocytes, and thus can be used as a marker for treating diabetes and obesity and developing new medicines therefor.Type: GrantFiled: April 30, 2014Date of Patent: October 3, 2017Assignee: Korea University Research and Business FoundationInventors: Je Sang Ko, Jeong-Han Kim
-
Patent number: 9771407Abstract: Preparations including recombinant FSH (rFSH).Type: GrantFiled: August 16, 2016Date of Patent: September 26, 2017Assignee: Ferring International Center SAInventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
-
Patent number: 9770482Abstract: A compound can destabilize an epidermal growth factor receptor (EGFR) protein and a sodium/glucose co-transporter 1 (SGLT 1) protein. In one embodiment, the compound is a peptide derived from the interacting domain of EGFR. In another embodiment, the peptide is administered to a patient to treat cancer.Type: GrantFiled: April 26, 2016Date of Patent: September 26, 2017Assignee: The University of Houston SystemInventor: Zhang Weihua
-
Patent number: 9757470Abstract: The present invention provides compositions and methods useful for delivering agents to target cells or tissues, for example nerve cells and other cells in the central nervous system. The compositions and methods are useful for delivering agents across the blood-brain barrier. The present invention also provides methods of using the compositions provided by the present invention to deliver agents, for example therapeutic agents for the treatment of neurologically related disorders.Type: GrantFiled: April 30, 2014Date of Patent: September 12, 2017Assignee: Children's Medical Center CorporationInventors: Manjunath Narasimhaswamy, Premlata Shankar, Priti Kumar
-
Patent number: 9655834Abstract: An isolated peptide for inhibiting melanogenesis in a mammal subject is provided. The isolated peptide consisting of an amino acid sequence of SSASTTED (SEQ ID NO: 1). Also provided are methods and compositions for inhibiting melanogenesis in a mammal subject.Type: GrantFiled: February 23, 2016Date of Patent: May 23, 2017Assignee: RENORIGIN INNOVATION INSTITUTE CO., LTD.Inventors: Hsiu-Chin Huang, Hsuan Lin
-
Patent number: 9657069Abstract: The present invention relates to a composition for preventing or treating cancer comprising Wnt decoy receptor. The composition of the present invention or the expression product thereof inhibits cancer generation, growth, proliferation and metastasis, and induces apoptosis of cancer cells, by binding to Wnt ligand and blocking ligand-receptor interactions, therefore may be effectively used as an anti-cancer agent.Type: GrantFiled: August 16, 2012Date of Patent: May 23, 2017Assignee: GENEMEDICINE CO., LTD.Inventors: Chae Ok Yun, Jung-Sun Lee
-
Patent number: 9649357Abstract: A method is disclosed for treating nephropathies involving undesired alternative pathway complement activation by administration of a complement inhibitory protein such as soluble complement receptor type I (sCR1).Type: GrantFiled: March 16, 2016Date of Patent: May 16, 2017Assignees: CELLDEX THERAPEUTICS, INC., UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Richard J. H. Smith, Yuzhou Zhang, Henry C. Marsh
-
Patent number: 9636377Abstract: The present invention relates to a pharmaceutical composition comprising an inhibitor of eIF2?, a compound increasing the expression and/or activity of protein BiP and/or an inhibitor of Caspase-12, preferably an inhibitor of eIF2? and a compound increasing the expression and/or activity of protein BiP. The present invention also relates to pharmaceutical compositions and methods for treating retinal degeneration related to ciliary dysfunction.Type: GrantFiled: February 25, 2013Date of Patent: May 2, 2017Assignee: UNIVERSITE DE STRASBOURGInventors: Vincent Marion, Anaïs Mockel, Hélène Dollfus
-
Patent number: 9631001Abstract: The invention relates to a new group of snake venom basic protease inhibitors having vasopressin-2 receptor antagonist activity that can be used in therapy, diagnosis, medical imaging, drug screening and research.Type: GrantFiled: September 17, 2013Date of Patent: April 25, 2017Assignees: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITY OF REGENSBURG, UNIVERSITY DE LIEGEInventors: Nicolas Gilles, Denis Servent, Loïc Quinton, Helen Reinfrank, Ralph Witzgall, Bernard Mouillac, Christiane Mendre
-
Patent number: 9623128Abstract: The present invention provides compositions and methods useful for diagnostic and imaging techniques for detecting and localizing the biomarker Plectin-1. The present invention provides multimeric peptide ligand complexes for targeting Plectin-1, such as the multimeric peptide ligand complex having the formula (?AKTLLPTPGGS(PEG5000))4 KKKKDOTA?A-NH2, to which imaging agents and/or therapeutic agents can be conjugated.Type: GrantFiled: March 27, 2015Date of Patent: April 18, 2017Assignee: University of Virginia Patent FoundationInventor: Kimberly A. Kelly
-
Patent number: 9624277Abstract: The present invention thus provides microbial products as anticancer agents and pharmaceutical compositions comprising isolated and purified proteins or synthetic peptides, and methods of using them for the treatment of cancer. It is very important to develop new anticancer bioactive peptides having high activity and low toxicity; given that most currently available anticancer therapies either have significant toxicity, and/or are prone to development of resistance.Type: GrantFiled: September 30, 2011Date of Patent: April 18, 2017Assignee: AMRITA THERAPEUTICS LIMITEDInventors: Anil Suri, Deepika Kanojia, Prabhakar Salunkhe, Sidharth Mahali, Sunil Kumar Manna, Avadhesha Surolia, Ananda Chakrabarty
-
Patent number: 9617324Abstract: To provide a peptide which can be produced and processed more readily compared with prothymosin ? , which is conventionally known, or a peptide thereof and has an activity at a level equivalent to or higher than that of prothymosin ? or a peptide thereof. The present invention provides an ameliorating agent for blood-organ barrier dysfunction, a therapeutic agent for diseases associated with blood-organ barrier dysfunction or ischemic diseases or a nerve cell death inhibitor, each comprising, as an active ingredient, a peptide comprising the amino acid sequence represented by SEQ ID NO: 1 or a peptide having substantially the same function as that of the aforementioned peptide.Type: GrantFiled: February 13, 2013Date of Patent: April 11, 2017Assignee: NAGASAKI UNIVERSITYInventor: Hiroshi Ueda
-
Patent number: 9618507Abstract: The present invention relates to methods for the treatment of rheumatoid arthritis. In particular, the present invention relates to methods of treating rheumatoid arthritis with GnRH antagonists in patients with high gonadotropin and/or GnRH levels.Type: GrantFiled: February 23, 2015Date of Patent: April 11, 2017Assignee: BETANIEN HOSPITALInventor: Anita Kass